Uridine Monophosphate (UMP)

Uridine monophosphate's mechanism of action as a nootropic is grounded in its role as a precursor for membrane phospholipid synthesis via the Kennedy pathway, with additional proposed effects on purinergic signalling, dopaminergic function, and synaptic plasticity. The Wurtman group at MIT has published the most detailed mechanistic and clinical work establishing these pathways.

1. The Kennedy pathway and phosphatidylcholine synthesis. The Kennedy pathway (CDP-choline pathway) is the primary route for phosphatidylcholine biosynthesis in mammalian cells. The pathway has three main steps:

• Step 1: Choline phosphorylation. Choline is phosphorylated by choline kinase to phosphocholine.
• Step 2: Activation to CDP-choline. Phosphocholine is condensed with cytidine triphosphate (CTP) by the enzyme CTP:phosphocholine cytidylyltransferase (CCT) — the rate-limiting enzyme of the pathway — to form CDP-choline (cytidine diphosphocholine).
• Step 3: Incorporation into phosphatidylcholine. CDP-choline is combined with diacylglycerol (DAG) by CDP-choline:1,2-diacylglycerol cholinephosphotransferase to form phosphatidylcholine, the major phospholipid of cellular membranes.

The availability of CTP — the cytidine nucleotide — is a significant controlling factor for the Kennedy pathway in the brain. In the mammalian brain (unlike many peripheral tissues), cytidine triphosphate is primarily synthesised from uridine triphosphate (UTP) via the enzyme CTP synthase, which aminates UTP to CTP. This makes uridine availability the upstream substrate for CTP production and, by extension, for CDP-choline and phosphatidylcholine synthesis.

Oral uridine supplementation raises plasma uridine, which crosses the blood-brain barrier via equilibrative nucleoside transporters (ENTs) and concentrative nucleoside transporters (CNTs), particularly CNT2. Inside brain cells, uridine is phosphorylated stepwise to UMP → UDP → UTP, and UTP is then converted to CTP. The end result is enhanced substrate availability for phosphatidylcholine synthesis, with downstream effects on membrane expansion, synaptic vesicle formation, dendritic spine density, and neurite outgrowth.

2. Synergy with choline and DHA. Phosphatidylcholine synthesis requires three substrates: choline, a cytidine/uridine nucleotide, and a diacylglycerol (with fatty acid tails). The Wurtman group demonstrated that supplementing all three components — uridine, choline, and docosahexaenoic acid (DHA) — produces additive/synergistic effects on brain phospholipid synthesis that exceed any single component alone. This is the mechanistic basis for the uridine-choline-DHA stack and for the Souvenaid formulation.

3. Dopaminergic effects. Rodent studies have reported that uridine supplementation increases dopamine release in the striatum and modulates dopamine receptor signalling. Wang, Pereira, Agnati, and others have described uridine's effects on dopaminergic function. The mechanism likely involves enhanced dopaminergic terminal membrane phospholipid supply supporting dopamine release machinery. This may contribute to proposed mood and motivation effects.

4. Purinergic receptor activation. Uridine, UDP, and UTP are ligands for P2Y receptors, a family of G-protein-coupled purinergic receptors expressed widely in the CNS and peripheral tissues. P2Y receptor activation has been implicated in:

• Microglial regulation and neuroinflammatory responses.
• Neuronal-glial communication.
• Synaptic plasticity modulation.
• Pain signalling (particularly in neuropathic pain contexts).

Whether supplemental uridine meaningfully modulates P2Y signalling at physiologically relevant concentrations is incompletely established.

5. Neurotrophic effects and synaptic plasticity. Uridine supplementation has been reported to increase dendritic spine density, promote neurite outgrowth, and support long-term potentiation (LTP) in hippocampal preparations. These effects are consistent with enhanced membrane phospholipid availability supporting the structural changes underlying learning and memory.

6. Neuroprotective effects. Preclinical studies in various brain injury models (ischaemia, toxic insults) suggest uridine and related pyrimidine nucleotides have neuroprotective effects, likely through supporting membrane repair after injury. The related compound CDP-choline (citicoline) has been more extensively studied clinically in stroke and traumatic brain injury, with variable results.

7. Peripheral effects relevant to CNS function. Uridine is also involved in peripheral glucose metabolism (via UDP-glucose), glycoprotein synthesis, and nucleic acid metabolism. Some of its systemic effects — on liver function, insulin sensitivity, and inflammation — may indirectly affect CNS function, though these connections are less well established.

Pharmacokinetics.

• Oral bioavailability of uridine (the free nucleoside): variable but generally adequate; much of dietary uridine is metabolised in enterocytes and liver before reaching systemic circulation.
• Oral UMP (uridine monophosphate) appears to have higher effective bioavailability than free uridine for raising brain uridine levels, possibly because UMP is partially resistant to first-pass breakdown or because phosphorylated uridine is a preferred substrate for certain transporters.
• Plasma uridine peaks approximately 1-2 hours after oral UMP administration.
• Half-life of exogenous uridine in plasma: approximately 2-4 hours.
• CNS uptake: saturable nucleoside transporters move uridine across the blood-brain barrier.
• Metabolism: primarily intracellular phosphorylation to UMP, UDP, UTP; excess uridine is catabolised to uracil, dihydrouracil, β-alanine, and eventually carbon dioxide and water via uridine phosphorylase and related enzymes.

What uridine does NOT do:

• It does NOT produce acute psychoactive effects — no alertness change, euphoria, or sedation on first dose.
• It does NOT function as a classical neurotransmitter at typical supplemental doses.
• It does NOT replace the function of approved cognitive enhancers (donepezil, memantine) in Alzheimer's disease.
• It does NOT replace evidence-based antidepressants for major depression.
• It does NOT raise IGF-1 or affect growth hormone signalling.

Uridine monophosphate (UMP, also written 5'-UMP or uridine-5'-monophosphate) is the nucleotide form of uridine, consisting of the pyrimidine base uracil linked to a ribose sugar phosphorylated at the 5' position. It is one of the four building blocks of RNA (the others being adenosine monophosphate, guanosine monophosphate, and cytidine monophosphate) and serves as a precursor in multiple biochemical pathways central to membrane phospholipid synthesis, carbohydrate metabolism (as UDP-glucose, UDP-galactose), glycoprotein and glycolipid synthesis (as UDP-GlcNAc, UDP-GalNAc), and purinergic neurotransmission (through UDP and UTP acting on P2Y receptors). Food sources include liver (particularly calf and beef liver), fish (sardines, herring, anchovies), broccoli, beer yeast, and human breast milk — the last being notable because uridine is an abundant and biologically important constituent of mammalian breast milk, supplying developing infants with substantial nucleotide building blocks for rapid cell division and membrane synthesis during early growth.

As a nootropic supplement, uridine monophosphate is primarily discussed in the context of cognitive function, mood, and neuroplasticity, based on its role as a substrate for the Kennedy pathway of membrane phosphatidylcholine synthesis. When supplemented orally at nootropic doses (typically 150-500 mg/day), uridine enters circulation, crosses the blood-brain barrier via specialised nucleoside transporters (ENT and CNT family), and is incorporated into brain cytidine triphosphate (CTP) — which is then condensed with choline (via choline kinase and CTP:phosphocholine cytidylyltransferase) to form CDP-choline, the activated intermediate used in phosphatidylcholine synthesis. Phosphatidylcholine is the predominant phospholipid of neuronal membranes and synaptic vesicles, and its availability is rate-limiting for the formation of new synapses during learning, memory formation, and neural repair.

This mechanistic pathway — uridine provides the pyrimidine backbone for CDP-choline synthesis, which drives phosphatidylcholine production, which supports synaptic growth — is the central logical framework for uridine's nootropic use. It also explains why uridine is commonly stacked with a choline source (alpha-GPC, CDP-choline, or choline bitartrate) and with DHA (docosahexaenoic acid, an omega-3 fatty acid) — the three components together provide the pyrimidine, choline, and fatty acid substrates that collectively support membrane phospholipid synthesis. The Richard Wurtman group at MIT published substantial preclinical and clinical work in the 2000s and 2010s establishing this uridine-choline-DHA synergy and showing benefits in animal models of cognitive impairment and, in selected human populations, modest cognitive effects. The most clinically significant application has been as a component of Souvenaid (brand-name medical food containing uridine monophosphate, choline, DHA/EPA, phospholipids, B-vitamins, and antioxidants), studied in early Alzheimer's disease with moderate-quality data showing some benefit on memory composite scores in prodromal and mild Alzheimer's populations.

Beyond the Alzheimer's-adjacent use, uridine has been studied and discussed in several other contexts: (1) major depressive disorder, particularly in work by Perry Renshaw and colleagues at McLean Hospital/Harvard on bipolar depression and unipolar depression, with some studies showing antidepressant signal; (2) bipolar disorder, with smaller studies suggesting potential benefit; (3) post-stroke cognitive recovery, with preliminary data; (4) pain syndromes including peripheral neuropathy, where pyrimidine nucleotide supplementation (cytidine + uridine) has been studied for nerve regeneration; and (5) general nootropic use in healthy adults, where the evidence is weakest and largely anecdotal.

It is important to place uridine honestly in the therapeutic landscape. For Alzheimer's disease, the evidence-based treatments are cholinesterase inhibitors (donepezil, rivastigmine, galantamine), memantine, and the newer disease-modifying antibodies lecanemab and donanemab — all of which have substantially more rigorous trial evidence than uridine. Souvenaid (the uridine-containing medical food) has a modest evidence signal for prodromal/mild Alzheimer's but is not a replacement for approved therapies. For depression, the evidence-based treatments are SSRIs, SNRIs, and for treatment-resistant depression, ketamine/esketamine, TMS, and ECT. Uridine as monotherapy for depression is not evidence-based, but it has emerging data as a potential adjunct in bipolar depression. For general cognitive enhancement in healthy adults, the evidence is preliminary at best, and the best-evidenced interventions remain sleep, exercise, nutrition, and cognitive engagement.

Where uridine has a genuine, reasonably well-supported role is: (1) as a component of the Souvenaid/uridine-choline-DHA stack for prodromal and mild Alzheimer's under physician guidance; (2) as a general supplement for membrane health and potentially mild cognitive support in older adults with concern about cognitive decline; (3) as an adjunct in bipolar depression under psychiatric supervision in research contexts; and (4) as a generally safe, low-risk nutritional supplement that forms part of various nootropic stacks without dramatic effects but also without significant risk when used sensibly.

From a safety perspective, uridine is one of the safer supplements in the nootropic space. It is a naturally occurring nutrient present in ordinary dietary sources, including breast milk. Typical supplemental doses (150-500 mg/day) are multiples of ordinary dietary intake (dietary uridine is difficult to quantify precisely but typical Western diets provide perhaps 5-50 mg/day of free uridine plus substantial nucleotide-derived uridine), but well below toxic levels. Human studies with daily doses up to 2 grams have shown good tolerability. Gout is a theoretical concern because uridine is a purine-adjacent nucleotide and its metabolism produces allantoin and, through some pathways, uric acid — but in practice, supplemental uridine does not appear to cause clinically significant hyperuricemia at typical doses.

Uridine is commonly combined with other nootropic compounds in community stacks: with choline sources (alpha-GPC, CDP-choline) for membrane synthesis support; with omega-3 DHA for the same purpose; with noopept or piracetam as part of broader cognitive-support stacks; with lions-mane for neurotrophic support; and with nad or other metabolic co-factors. The evidence for specific combinations is generally mechanistic/anecdotal rather than trial-validated.

IUPAC Name

{[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxyoxolan-2-yl]methyl} dihydrogen phosphate

CAS Number

58-97-9

Molecular Formula

C9H13N2O9P

Molecular Mass

324.18 g/mol

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Interaction Matrix

Get Uridine Monophosphate (UMP) Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Related Compounds

Data Completeness

Research Credibility